Skip to main content
. 2017 May 17;20(2):253–262. doi: 10.1093/europace/eux022

Figure 3.

Figure 3

Cumulative incidence of the primary RE-LY study outcome in the three randomized groups in patients without (left panel) and with (right panel) left ventricular hypertrophy. CI, confidence interval; DE, dabigatran etexilate; HR, hazard ratio; LVH, left ventricular hypertrophy.